E.Lilly to pay $62 mln to settle Zyprexa case -NYT
Oct 7 (Reuters) - Eli Lilly and Co (LLY.N) has agreed to pay $62 million to settle claims that it improperly marketed its blockbuster schizophrenia drug, Zyprexa, to patients who were not approved users, the New York Times said on its website.
The settlement with 33 states, to be announced Tuesday, ends an 18-month investigation led by the offices of the attorneys-general of Illinois and Oregon, the paper said.
The paper said the agreement may portend a deal with Philadelphia, where Lilly is expected to pay more than $1 billion in fines and may also plead guilty to a misdemeanor criminal charge related to off-label marketing of Zyprexa.
Zyprexa is an anti-psychotic drug that calms hallucinations associated with schizophrenia and bipolar mania but internal Lilly documents and e-mail messages appear to show that the drug was marketed to patients with dementia and milder forms of bipolar disorder, the paper added.
A spokesman and a lawyer for Lilly did not return a call and an e-mail message for comment, the paper said.
The company could not be immediately reached for comment by Reuters. (Reporting by Savio D'Souza in Bangalore; Editing by Quentin Bryar)










